Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed)

Active
No
Status
Posted
Published Date
November 17th, 2023
Close Date
March 13th, 2024
Opportunity No.
RFA-DA-25-030

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health is offering a grant opportunity titled "Adolescent Overdose Prevention and SUD Treatment Initiative (R21 - Clinical Trial Not Allowed)". This grant aims to support exploratory and developmental research to better understand adolescent illicit fentanyl use and overdose patterns among youth at high risk for overdose. The research studies funded by this grant should identify targets for overdose prevention and substance use disorder (SUD) treatment and recovery. Various research approaches can be used, such as leveraging existing data sources, survey research, social network analysis, new methods development, and feasibility research. The outcomes of interest include the prevalence of overdose and reduction in substance use, particularly fentanyl use or use of drugs commonly laced with fentanyl, unintentional use/overdose, use/overdose by risk group, stigma, family and environmental risk and protective factors, treatment engagement, youth perceptions of substance use, and optimistic bias. The grant does not require cost sharing or matching. The deadline for application submission is March 13, 2024. For more information and to apply, visit the following link: Adolescent Overdose Prevention and SUD Treatment Initiative Grant.

Description

This Funding Opportunity Announcement (FOA) encourages exploratory and developmental research to better understand adolescent illicit fentanyl use and overdose patterns among youth at high risk for overdose. Research studies should identify targets for overdose prevention and substance use disorder (SUD) treatment and recovery. Research studies may use a variety of approaches (e.g., leveraging existing data sources, survey research, social network analysis, new methods development, feasibility research). Outcomes of interest include but are not limited to prevalence of overdose and reduction in substance use, particularly fentanyl use or use of drugs that are commonly laced with fentanyl; unintentional use/overdose, use/overdose by risk group, stigma, family and environmental risk and protective factors, treatment engagement, youth perceptions of substance use, and optimistic bias.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)". This grant aims to support innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors, prevention of drug use and HIV, and health service utilization. The grant encourages the analysis of public use and other extant community-based or clinical datasets to increase our knowledge of drug using behaviors and their consequences, as well as strategies for prevention and treatment. The grant has a funding ceiling of $275,000 and does not require cost sharing or matching. The deadline for applications is November 15, 2024. For more information and to apply, visit the following link: [Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-037.html).
Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a federal grant opportunity titled "Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)". This grant aims to support the discovery and development of medications to prevent and treat opioid and/or psychostimulant use disorders and overdose. The funding instrument type for this opportunity is a Cooperative Agreement. The grant falls under the category of funding activity related to health. The grant does not require cost sharing or matching. The eligible applicants for this grant include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The purpose of this grant is to support the discovery and development of medications that can prevent and treat opioid and/or psychostimulant use disorders and overdose. The grant involves two phases, UG3 and UH3. The UG3 phase provides support for a project with specific milestones to be accomplished within a 2-year period. The UH3 phase provides funding for 3 years to a project that successfully completes the milestones set in the UG3 phase. Projects that meet their milestones in the UG3 phase will be considered for transition to the UH3 phase. The grant encourages applications that include preclinical or clinical research studies with high impact and quick results to advance medications closer to FDA approval for the prevention and treatment of opioid use disorders and overdose. The compounds to be evaluated can be small molecules or biologics, and they can be tested in pre-clinical models or for the clinical manifestations of opioid use disorders such as withdrawal, craving, relapse, or overdose. The grant also supports the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of opioid use disorders and overdose. The goal of this grant is to fast-track the discovery and development of medications to prevent and treat opioid use disorders or opioid overdose and advance them in the FDA's drug development approval pipeline. For more information and to apply for this grant opportunity, please visit the following link: [Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)](http://grants.nih.gov/grants/guide/pa-files/PAR-22-200.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)". This grant aims to support pilot, feasibility, or exploratory research in substance use epidemiology and health services. The research will focus on five priority areas, including responses to sudden and severe emerging drug issues, responses to emerging marijuana trends and topics related to the shifting policy landscape, responses to unexpected and time-sensitive prescription drug abuse research opportunities, responses to unexpected and time-sensitive medical system issues, and responses to unexpected and time-sensitive criminal or juvenile justice opportunities that relate to drug abuse and access and provision of health care service. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities, Indian/Native American Tribal Governments, Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities, U.S. Territory or Possession. Non-domestic (non-U.S.) Entities (Foreign Institutions) and non-domestic components of U.S. Organizations are not eligible to apply. The grant does not require cost sharing or matching requirements. The funding instrument type is a grant, and the category of funding activity is health. The maximum award ceiling is $275,000. The deadline for application submission is September 8, 2024. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html). If you have any inquiries, you can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)". This grant aims to support innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of drug using behaviors, prevention of drug use and HIV, and health service utilization. The grant encourages the analysis of public use and other extant community-based or clinical datasets to increase our knowledge of drug using behaviors and their consequences, as well as strategies for prevention and treatment of drug abuse and HIV. The grant does not require cost sharing or matching. The deadline for application submission is November 15, 2024. For more information and to apply, please visit the following link: [Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-037.html).